Single linker FabFv antibodies and methods of producing same

Patent metadata

Field	Value
Publication number	US-11401349-B2
Application number	US-201916573893-A
Country	US
Kind code	B2
Filing date	Sep 17, 2019
Priority date	Dec 21, 2012
Publication date	Aug 2, 2022
Grant date	Aug 2, 2022

Abstract

The present disclosure relates to a multi-specific antibody molecule comprising or consisting of three polypeptides: a) a polypeptide chain of formula (I):(Vxx)nVx-Cx-X-V1; and b) a polypeptide chain of formula (II): (Vyy)nVy-Cy c) a polypeptide of formula (III):V2 wherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region, X represents a linker, V represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region, V2 represents a variable domain, nindependently represents 0 or 1, wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired and the variable domains Vx and Vy are paired to form a binding domain and optionally a disulphide bond is present between V1 and V2, in particular where a disulphide bond is present. The disclosure also extends to pharmaceutical formulation comprising the construct, DNA encoding the constructs and vectors comprising same. The disclosure further extends to a method of expressing the constructs, for example in a host cell and methods for formulating same as a pharmaceutical composition. The disclosure also relates to use of the constructs and formulations in treatment.

First claim

The invention claimed is:

1. An antibody molecule consisting of three polypeptides,
(a) a polypeptide chain of formula (I):
(Vxx) n Vx-Cx-X-V 1 ,

(b) a polypeptide chain of formula (II):
(Vyy) n Vy-C y , and

(c) a polypeptide of formula (III):
V 2 ,

wherein:

Vx represents a variable domain,
Vxx represents a variable domain,
Cx represents a constant region consisting of C L or CH 1 ,
X represents a linker,
V 1 represents a variable domain,
Vy represents a variable domain,
Vyy represents a variable domain,
Cy represents a constant region consisting of C L or CH 1 ,
V 2 represents a variable domain,
n represents 0 or 1;
wherein only one of Cx or Cy is CH 1 ;
wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired, the variable domains Vx and Vy are paired to form a binding domain, the variable domains V 1 and V 2 are paired to form a binding domain, and a disulphide bond is present between V 1 and V 2 ;
wherein n is either 0 in the polypeptide chains of formula (I) and (II), or n is 1 in the polypeptide chains of formula (I) and (II) and the variable domains Vxx and Vyy are paired to form a binding domain;
wherein the variable domain pair V 1 /V 2 are linked by a disulfide bond between two engineered cysteine residues, one in V 1 and one in V 2 ; and
wherein the position of the pair of engineered cysteine residues is selected from the group consisting of VH37 and VL95, VH44 and VL100, VH44 and VL105, VH45 and VL87, VH100 and VL50, VH100b and VL49, VH98 and VL46, VH101 and VL46, VH105 and VL43, and VH106 and VL57.

2. The antibody molecule of claim 1 , wherein
(a) in the polypeptide chain of formula (I), n is 0 and Vx is V L ,
(b) in the polypeptide chain of formula (II), n is 0 and Vy is V H ,
(c) V H represents a heavy chain variable domain, and
(d) V L represents a light chain variable domain.

3. The antibody molecule of claim 1 , wherein Cx is C L , V 1 represents a light chain variable domain and V 2 represents a heavy chain variable domain.

4. The antibody molecule of claim 1 , wherein Cx is CH 1 , V 1 represents a heavy chain variable domain and V 2 represents a light chain variable domain.

5. The antibody molecule of claim 1 , wherein the variable domain pair V 1 /V 2 have specificity for a serum carrier protein.

6. The antibody molecule of claim 5 , wherein V 2 comprises the sequence of SEQ ID NO:87 for CDRH-1, the sequence of SEQ ID NO:88 for CDRH2 and the sequence of SEQ ID NO:89 for CDRH-3 and V 1 comprises the sequence of SEQ ID NO:90 for CDRL-1, the sequence of SEQ ID NO:91 for CDRL2 and the sequence of SEQ ID NO:92 for CDRL-3.

7. The antibody molecule of claim 5 , wherein V 2 comprises the sequence of SEQ ID NO:93 for CDRH-1, the sequence of SEQ ID NO:94 for CDRH2 and the sequence of SEQ ID NO:95 for CDRH-3 and V 1 comprises the sequence of SEQ ID NO:96 for CDRL-1, the sequence of SEQ ID NO:97 for CDRL2 and the sequence of SEQ ID NO:98 for CDRL-3.

8. The antibody molecule of claim 1 , wherein X comprises the sequence of SEQ ID NO:103.

9. The antibody molecule of claim 1 , wherein a natural disulfide bond is present between Cx and Cy.

10. The antibody molecule of claim 1 , wherein at least one binding domain of the antibody molecule is specific for an antigen that is an immunoglobulin, an interferon, a colony stimulating factor, a viral antigen, a member of the classical and alternative complement activation cascade, an FcγR, a complement pathway protein, an integrin, or an interleukin.

11. The antibody molecule of claim 10 , wherein the at least one binding domain is specific for IgE.

12. The antibody molecule of claim 10 , wherein the at least one binding domain is specific for an interferon that is interferon α, interferon β, or interferon γ.

13. The antibody molecule of claim 10 , wherein the at least one binding domain is specific for a colony stimulating factor that is G-CSF or GM-CSF.

14. The antibody molecule of claim 10 , wherein the at least one binding domain is specific for a viral antigen that is a respiratory syncytial virus or cytomegalovirus, influenza, EBV, HepA, B, or C antigen.

15. The antibody molecule of claim 10 , wherein the at least one binding domain is specific for a member of the classical and alternative complement activation cascade that is C2, C4, C3-convertase, C5, C6, C7, C8, or C9.

16. The antibody molecule of claim 10 , wherein the at least one binding domain is specific for an FcγR that is FcγRI, FcγRII, or FcγRIII.

17. The antibody molecule of claim 10 , wherein the at least one binding domain is specific for a complement pathway protein that is C1q or C3.

18. The antibody molecule of claim 10 , wherein the at least one binding domain is specific for an integrin that is β1 integrin, VLA-4, E-selectin, P selectin, or L-selectin.

19. The antibody molecule of claim 10 , wherein the at least one binding domain is specific for an interleukin that is IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-12, IL-16, IL-17, or IL-23.

20. The antibody molecule of claim 1 , wherein at least one binding domain of the antibody molecule is specific for an antigen independently selected from the group consisting of an integrin, ICOS, BCMP7, CDCP1, DPCR1, DPCR1, dudulin2, FLJ20584, FLJ40787, HEK2, KIAA0634, KIAA0659, KIAA1246, KIAA1455, LTBP2, LTK, MAL2, MRP2, nectin-like2, NKCC1, PTK7, RAIG1, TCAM1, SC6, BCMP101, BCMP84, BCMP11, DTD, carcinoembryonic antigen (CEA), human milk fat globulin, MHC Class I and MHC Class II antigens, VEGF, an interleukin, a viral antigen, an immunoglobulin, an interferon, tumour necrosis factor-α, tumor necrosis factor-β, a colony stimulating factor, a platelet derived growth factor, a bacterial antigen, a snake and spider venom and toxin, OX40, histamine, C1q, opsonin, a member of the classical and alternative complement activation cascades, a FcγR, a complement pathway protein, a CD (Cluster of Differentiation) marker protein, a serum carrier protein, a circulating immunoglobulin molecule, and CD35/CR1.

21. The antibody molecule of claim 20 , wherein the CD marker protein is independently selected from the group consisting of CD2, CD3, CD4, CD5, CD7, CD8, CD11a, CD11b, CD18, CD19, CD20, CD23, CD25, CD33, CD38, CD40, CD45, CD69, CD134, CD137 and CD27L.

22. The antibody molecule of claim 1 , wherein C L represents Ckappa or Clambda.

23. A pharmaceutical composition, comprising the antibody molecule of claim 1 and at least one excipient.

24. A set of three polynucleotides, each polynucleotide encoding a different polypeptide chain of the antibody molecule of claim 7 .

25. A vector, comprising the polynucleotides of claim 24 .

26. A host cell, comprising the polynucleotides of claim 24 .

27. A host cell, comprising three vectors, each vector comprising a polynucleotide encoding a different polypeptide chain of the antibody molecule of claim 1 .

28. A process, comprising expressing an antibody molecule from the host cell of claim 26 .

Assignees

• Ucb Biopharma Sprl
• UCB Biopharma SRL

Inventors

• Dave Emma
• Heywood Sam Philip
• Humphreys David Paul

Classifications

• A61P19/10

  for osteoporosis · CPC title

• A61P25/04

  Centrally acting analgesics, e.g. opioids · CPC title

• C07K16/18

  against material from animals or humans · CPC title

• C07K2319/00

  Fusion polypeptide · CPC title

• A61P31/04

  Antibacterial agents · CPC title